| Balance Sheets | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 100,376 | 33,880 | 37,940 | 50,347 |
| Short-term investments available for sale | 614,194 | 773,844 | 813,918 | 880,093 |
| Prepaid clinical trial and preclinical study costs | 21,891 | 16,478 | 13,300 | 4,476 |
| Prepaid expenses and other current assets | 2,242 | 2,815 | 865 | 1,733 |
| Total current assets | 738,703 | 827,017 | 866,023 | 936,649 |
| Right-of-use assets | 666 | 780 | 892 | 1,113 |
| Deferred financing costs | 0 | 8 | 32 | 80 |
| Deposits | 46 | 46 | 46 | 46 |
| Total assets | 739,415 | 827,851 | 866,993 | 937,888 |
| Accounts payable | 4,413 | 5,494 | 7,702 | 254 |
| Other accrued liabilities | 21,217 | 26,018 | 11,373 | 24,951 |
| Lease liability, current | 437 | 468 | 498 | 480 |
| Total current liabilities | 26,067 | 31,980 | 19,573 | 25,685 |
| Lease liability, net of current portion | 318 | 410 | 502 | 755 |
| Total long-term liabilities | 318 | 410 | 502 | 755 |
| Total liabilities | 26,385 | 32,390 | 20,075 | 26,440 |
| Common stock, 0.00001 par value 300,000,000 shares authorized at september 30, 2025 and december 31, 2024 112,446,961 shares issued and outstanding at september 30, 2025 and 111,573,519 shares issued and outstanding at december 31, 2024 | 1 | 1 | 1 | 1 |
| Treasury stock at cost, no shares at september 30, 2025 and december 31, 2024 | 0 | 0 | 0 | 0 |
| Additional paid-in capital | 1,402,539 | 1,394,723 | 1,380,669 | 1,362,305 |
| Accumulated deficit | -689,884 | -599,097 | -533,536 | -452,490 |
| Accumulated other comprehensive loss | 374 | -166 | -216 | 1,632 |
| Total stockholders equity | 713,030 | 795,461 | 846,918 | 911,448 |
| Total liabilities and stockholders equity | 739,415 | 827,851 | 866,993 | 937,888 |
Viking Therapeutics, Inc. (VKTX)
Viking Therapeutics, Inc. (VKTX)